| Name | Title | Contact Details |
|---|
Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Epitopix is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.